Cytek Biosciences
CTKB
158 hedge funds and large institutions have $270M invested in Cytek Biosciences in 2025 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 65 increasing their positions, 47 reducing their positions, and 27 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 47
2.17% more ownership
Funds ownership: 60.51% → 62.68% (+2.2%)
7% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 27
1% less funds holding
Funds holding: 160 → 158 (-2)
13% less capital invested
Capital invested by funds: $311M → $270M (-$40.9M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Topline Capital Management
Santa Monica,
California
|
+$12.5M |
| 2 |
RA
Royce & Associates
New York
|
+$2.75M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.95M |
| 5 |
Millennium Management
New York
|
+$1.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.19M |
| 2 |
BlackRock
New York
|
-$3.44M |
| 3 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
-$3.39M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.7M |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$1.68M |
CTKB Hedge Fund Activity: Q2 2025 in Review
158 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q2 2025, worth a combined $270M — down 13% from $311M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of CTKB and 25 opened new positions — a net loss of 2 holders — while 47 trimmed existing stakes and 65 added.
The largest buyer was Topline Capital Management, adding an estimated $12.5M. The largest seller was Vanguard Group, cutting an estimated $6.19M.
- 158 institutional investors held Cytek Biosciences (CTKB) as of Q2 2025, down from 160 in Q1 2025.
- Funds reported $270M of Cytek Biosciences stock for Q2 2025, down 13% quarter-over-quarter.
- 25 funds opened new Cytek Biosciences positions in Q2 2025 and 27 closed out, a net change of -2 holders.
- The largest Cytek Biosciences buyer in Q2 2025 was Topline Capital Management, an estimated $12.5M added.
- The largest Cytek Biosciences seller in Q2 2025 was Vanguard Group, an estimated $6.19M sold.
Based on aggregated 13F filings for Q2 2025.